产前静脉注射铁和儿童生长:随机临床试验的二次分析
Glory Mzembe1,2, William Nkhono1, Ernest Moya1,2
1Training and Research Unit of Excellence, Blantyre, Malawi.
JAMA network open
|October 28, 2025
概括
与标准口服铁相比,给患有贫血的孕妇静脉注射铁 (铁性碳酸) 并没有改善婴儿的生长. 这项研究发现,产后12个月的儿童生长结果没有显著差异.
科学领域:
- 孕产妇和儿童的健康
- 营养科学 营养科学
- 临床试验 临床试验
背景情况:
- 怀孕期间母亲的贫血与孩子的生长不良有关.
- 静脉注射铁在改善产后儿童发育方面的有效性尚不清楚.
研究的目的:
- 评估静脉注射的铁性碳酸 (FCM) 是否与标准口服铁 (SOC) 相比,在患有中度至重度贫血的孕妇中增强了婴儿的生长.
- 这是REVAMP随机临床试验的二次分析.
主要方法:
- 在马拉维,患有贫血 (血红蛋白5-10 g/dL) 的孕妇从怀孕13-26周接受了静脉注射FCM或口服硫酸铁 (SOC).
- 产后12个月监测婴儿的成长,测量长度与年龄的z分数 (LAZ),体重与年龄的z分数 (WAZ) 和体重与长度的z分数 (WLZ).
- 混合效应模型被用来分析增长结果的重复测量.
主要成果:
- 在12个月后,FCM和SOC组之间没有观察到平均LAZ,WAZ或WLZ的显著差异.
- 发育迟缓,体重不足和衰减的发生率在接受FCM和SOC的母亲生下的婴儿之间没有区别.
- 较年轻的年龄,较矮的身材和较低的教育水平等母亲因素与增长迟缓有关,但治疗效应没有显示异质性.
结论:
- 在怀孕期间对孕妇贫血进行静脉注射铁碳糖治疗,并没有导致婴儿生长在产后12个月内显著改善.
- 研究结果表明,与标准口服铁相比,静脉注射铁可能不会为婴儿提供显著的生长益处.
- 可能需要进一步的研究来探索其他潜在的益处或替代性干预对母亲贫血.
相关概念视频
01:29Drug Dosing: Infants and Children
226
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
226
01:15Bioavailability Study Design: Healthy Subjects Versus Patients
126
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
126
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
231
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
231
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
165
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
165
01:07Teratogenicity
3.9K
The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
3.9K
01:11Bioavailability Study Design: Single Versus Multiple Dose Studies
170
Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
170